Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

The presence of anti-CD4 autoantibodies in treatment-naive patients with advanced HIV was associated with a decreased rate of CD4 reconstitution following ART initiation.

An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence ...

An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025IMC-M113V was well ...

Your IP is registered with the company mentioned above and provides access to Life Science Sweden.

An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.

Protein crystallization at the SER-CAT beamline at Argonne’s Advanced Photon Source proved key to the discovery of a new HIV vaccine candidate.

aCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA bDepartment of Pathology and Laboratory Medicine, University of Pennsylvania ...

Rapid antigen-based testing has been widely adopted in diagnostic laboratories for ease and speed of use: results are available within minutes. The presence of RSV in the clinical specimen ...

The rarest blood type is Rhnull. Unlike other blood types, people with Rhnull blood have no Rh antigens on their red blood cells. Healthcare professionals classify blood type according to the ...